Identification of prostaglandin E2 receptor subtype 2 as a receptor activated by OxPAPC

Circulation Research

Volumn 98, Issue 5, 2006, Pages 642-650

  Li, Rongsong ^a   Mouillesseaux, Kevin P ^a   Montoya, Dennis ^a   Cruz, Daniel ^a   Gharavi, Navid ^a   Dun, Martin ^a   Koroniak, Lukasz ^a   Berliner, Judith A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; EP2; GPCR; Monocyte binding; OxPAPC; Receptor

Indexed keywords

1 PALMITOYL 2 ARACHIDONOYLGLYCERO 3 PHOSPHORYLCHOLINE; 1 PALMITOYL 2 EPOXYISOPROSTANE E2 GLYCERO 3 PHOSPHORYLCHOLINE; 6 ISOPROPOXY 9 OXO 2 XANTHENECARBOXYLIC ACID; BETA1 INTEGRIN; BUTAPROST; FATTY ACID; FIBRONECTIN; G PROTEIN COUPLED RECEPTOR; INTERLEUKIN 10; MESSENGER RNA; PHOSPHOLIPID; PHOSPHORYLCHOLINE; PROSTAGLANDIN D2; PROSTAGLANDIN E RECEPTOR; RECEPTOR SUBTYPE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; 1 PALMITOYL 2 (5 OXOVALEROYL) SN GLYCERO 3 PHOSPHORYLCHOLINE; 1 PALMITOYL 2 (EPOXYISOPROSTANE E2) SN GLYCERO 3 PHOSPHOCHOLINE; 1-PALMITOYL-2-(5-OXOVALEROYL)-SN-GLYCERO-3-PHOSPHORYLCHOLINE; 1-PALMITOYL-2-(EPOXYISOPROSTANE-E2)-SN-GLYCERO-3-PHOSPHOCHOLINE; 6-ISOPROPOXY-9-OXOXANTHENE-2-CARBOXYLIC ACID; DRUG DERIVATIVE; ETHER PHOSPHOLIPID; ISOPROSTANE DERIVATIVE; PHOSPHATIDYLCHOLINE; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROSTAGLANDIN EP2 RECEPTOR; XANTHONE DERIVATIVE;

ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CELL STRAIN HEK293; CHRONIC INFLAMMATION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; LIGAND BINDING; MACROPHAGE; MONOCYTE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REPORTER GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; BIOSYNTHESIS; CELL CULTURE; DRUG EFFECT; FOAM CELL; GENETICS; METABOLISM; OXIDATION REDUCTION REACTION; PHYSIOLOGY;

ALPROSTADIL; ATHEROSCLEROSIS; CELLS, CULTURED; DINOPROSTONE; FOAM CELLS; HUMANS; INTERLEUKIN-10; ISOPROSTANES; MACROPHAGES; MONOCYTES; OXIDATION-REDUCTION; PHOSPHATIDYLCHOLINES; PHOSPHOLIPID ETHERS; RECEPTORS, PROSTAGLANDIN E; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; XANTHONES;

EID: 33645323281     PISSN: 00097330     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.RES.0000207394.39249.fc     Document Type: Article

References (33)

1. Berliner JA, Subbanagounder G, Leitinger N, Watson AD, Vora D. Evidence for a role of phospholipid oxidation products in atherogenesis. Trends Cardiovasc Med. 2001;11:142-147.
2. Leitinger N. Oxidized phospholipids as modulators of inflammation in atherosclerosis. Curr Opin Lipidol. 2003;14:421-430.
3. Cole AL, Subbanagounder G, Mukhopadhyay S, Berliner JA, Vora DK. Oxidized phospholipid-induced endothelial cell/monocyte interaction is mediated by a cAMP-dependent R-Ras/PI3-kinase pathway. Arterioscler Thromb Vasc Biol. 2003;23:1384-1390.
4. Leitinger N, Tyner TR, Oslund L, Rizza C, Subbanagounder G, Lee H, Shih PT, Mackman N, Tigyi G, Territo MC, Berliner JA, Vora DK. Structurally similar oxidized phospholipids differentially regulate endothelial binding of monocytes and neutrophils. Proc Natl Acad Sci U S A. 1999;96:12010-12015.
5. Shih PT, Elices MJ, Fang ZT, Ugarova TP, Strahl D, Territo MC, Frank JS, Kovach NL, Cabanas C, Berliner JA, Vora DK. Minimally modified low-density lipoprotein induces monocyte adhesion to endothelial connecting segment-1 by activating beta1 integrin. J Clin Invest. 1999;103: 613-625.
6. Parhami F, Fang ZT, Fogelman AM, Andalibi A, Territo MC, Berliner JA. Minimally modified low density lipoprotein-induced inflammatory responses in endothelial cells are mediated by cyclic adenosine monophosphate. J Clin Invest. 1993;92:471-478.
7. Parhami F, Fang ZT, Yang B, Fogelman AM, Berliner JA. Stimulation of Gs and inhibition of Gi protein functions by minimally oxidized LDL. Arterioscler Thromb Vasc Biol. 1995;15:2019-2024.
8. Watson AD, Subbanagounder G, Welsbie DS, Faull KF, Navab M, Jung ME, Fogelman AM, Berliner JA. Structural identification of a novel pro-inflammatory epoxyisoprostane phospholipid in mildly oxidized low density lipoprotein. J Biol Chem. 1999;274:24787-24798.
9. Seager Danciger J, Lutz M, Hama S, Cruz D, Castrillo A, Lazaro J, Phillips R, Premack B, Berliner J. Method for large scale isolation, culture and cryopreservation of human monocytes suitable for chemotaxis, cellular adhesion assays, macrophage and dendritic cell differentiation. J Immunol Methods. 2004;288:123-134.
10. Abramovitz M, Adam M, Boie Y, Carriere M, Denis D, Godbout C, Lamontagne S, Rochette C, Sawyer N, Tremblay NM, Belley M, Gallant M, Dufresne C, Gareau Y, Ruel R, Juteau H, Labelle M, Ouimet N, Metters KM. The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000;1483:285-293.
11. Wilson RJ, Rhodes SA, Wood RL, Shield VJ, Noel LS, Gray DW, Giles H. Functional pharmacology of human prostanoid EP2 and EP4 receptors. Eur J Pharmacol. 2004;501:49-58.
12. Treffkorn L, Scheibe R, Maruyama T, Dieter P. PGE2 exerts its effect on the LPS-induced release of TNF-alpha, ET-1, IL-1alpha, IL-6 and IL-10 via the EP2 and EP4 receptor in rat liver macrophages. Prostaglandins Other Lipid Mediat. 2004;74:113-123.
13. Vassiliou E, Jing H, Ganea D. Prostaglandin E2 inhibits TNF production in murine bone marrow-derived dendritic cells. Cell Immunol. 2003;223:120-132.
14. Shinomiya S, Naraba H, Ueno A, Utsunomiya I, Maruyama T, Ohuchida S, Ushikubi F, Yuki K, Narumiya S, Sugimoto Y, Ichikawa A, Oh-ishi S. Regulation of TNFalpha and interleukin-10 production by prostaglandins I(2) and E(2): studies with prostaglandin receptor-deficient mice and prostaglandin E-receptor subtype-selective synthetic agonists. Biochem Pharmacol. 2001;61:1153-1160.
15. Woodward DF, Pepperl DJ, Burkey TH, Regan JW. 6-Isopropoxy-9-oxoxanthene- 2-carboxylic acid (AH 6809), a human EP2 receptor antagonist. Biochem Pharmacol. 1995;50:1731-1733.
16. Subbanagounder G, Wong JW, Lee H, Faull KF, Miller E, Witztum JL, Berliner JA. Epoxyisoprostane and epoxycyclopentenone phospholipids regulate monocyte chemotactic protein-1 and interleukin-8 synthesis. Formation of these oxidized phospholipids in response to interleukin-1beta. J Biol Chem. 2002;277:7271-7281.
17. Honda HM, Leitinger N, Frankel M, Goldhaber JI, Natarajan R, Nadler JL, Weiss JN, Berliner JA. Induction of monocyte binding to endothelial cells by MM-LDL: role of lipoxygenase metabolites. Arterioscler Thromb Vasc Biol. 1999;19:680-686.
18. Subbanagounder G, Leitinger N, Schwenke DC, Wong JW, Lee H, Rizza C, Watson AD, Faull KF, Fogelman AM, Berliner JA. Determinants of bioactivity of oxidized phospholipids. Specific oxidized fatty acyl groups at the sn-2 position. Arterioscler Thromb Vasc Biol. 2000;20:2248-2254.
19. Kedzie KM, Donello JE, Krauss HA, Regan JW, Gil DW. A single amino-acid substitution in the EP2 prostaglandin receptor confers responsiveness to prostacyclin analogs. Mol Pharmacol. 1998;54:584-590.
20. Fennekohl A, Sugimoto Y, Segi E, Maruyama T, Ichikawa A, Puschel GP. Contribution of the two Gs-coupled PGE2-receptors EP2-receptor and EP4-receptor to the inhibition by PGE2 of the LPS-induced TNFalpha-formation in Kupffer cells from EP2-or EP4-receptor-deficient mice. Pivotal role for the EP4-receptor in wild type Kupffer cells. J Hepatol. 2002;36:328-334.
21. Harizi H, Grosset C, Gualde N. Prostaglandin E2 modulates dendritic cell function via EP2 and EP4 receptor subtypes. J Leukoc Biol. 2003;73:756-763.
22. Stillman BA, Breyer MD, Breyer RM. Importance of the extracellular domain for prostaglandin EP(2) receptor function. Mol Pharmacol. 1999;56:545-551.
23. Tintut Y, Parhami F, Tsingotjidou A, Tetradis S, Territo M, Demer LL. 8-Isoprostaglandin E2 enhances receptor-activated NFkappa B ligand (RANKL)-dependent osteoclastic potential of marrow hematopoietic precursors via the cAMP pathway. J Biol Chem. 2002;277:14221-14226.
24. Clarke DL, Belvisi MG, Hardaker E, Newton R, Giembycz MA. E-Ring 8-isoprostanes are agonists at EP2- and EP4-prostanoid receptors on human airway smooth muscle cells and regulate the release of colony-stimulating factors by activating cAMP-dependent protein kinase. Mol Pharmacol. 2005;67:383-393.
25. Huber J, Bochkov VN, Binder BR, Leitinger N. The isoprostane 8-iso-PGE2 stimulates endothelial cells to bind monocytes via cyclic AMP- and p38 MAP kinase-dependent signaling pathways. Antioxid Redox Signal. 2003;5:163-169.
26. Foey AD, Field S, Ahmed S, Jain A, Feldmann M, Brennan FM, Williams R. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis. Arthritis Res Ther. 2003;5:R317-328.
27. Platzer C, Meisel C, Vogt K, Platzer M, Volk HD. Up-regulation of monocytic IL-10 by tumor necrosis factor-alpha and cAMP elevating drugs. Int Immunol. 1995;7:517-523.
28. Noguchi K, Iwasaki K, Shitashige M, Ishikawa I. Prostaglandin E2 receptors of the EP2 and EP4 subtypes downregulate tumor necrosis factor alpha-induced intercellular adhesion molecule-1 expression in human gingival fibroblasts. J Periodontal Res. 1999;34:478-485.
29. Yamane H, Sugimoto Y, Tanaka S, Ichikawa A. Prostaglandin E(2) receptors, EP2 and EP4, differentially modulate TNF-alpha and IL-6 production induced by lipopolysaccharide in mouse peritoneal neutrophils. Biochem Biophys Res Commun. 2000;278:224-228.
30. Huo Y, Hafezi-Moghadam A, Ley K. Role of vascular cell adhesion molecule-1 and fibronectin connecting segment-1 in monocyte rolling and adhesion on early atherosclerotic lesions. Circ Res. 2000;87:153-159.
31. Halvorsen B, Waehre T, Scholz H, Clausen OP, von der Thusen JH, Muller F, Heimli H, Tonstad S, Hall C, Froland SS, Biessen EA, Damas JK, Aukrust P. Interleukin-10 enhances the oxidized LDL-induced foam cell formation of macrophages by antiapoptotic mechanisms. J Lipid Res. 2005;46:211-219.
32. Pinderski LJ, Fischbein MP, Subbanagounder G, Fishbein MC, Kubo N, Cheroutre H, Curtiss LK, Berliner JA, Boisvert WA. Overexpression of interleukin-10 by activated T lymphocytes inhibits atherosclerosis in LDL receptor-deficient Mice by altering lymphocyte and macrophage phenotypes. Circ Res. 2002;90:1064-1071.
33. Lang R, Rutschman RL, Greaves DR, Murray PJ. Autocrine deactivation of macrophages in transgenic mice constitutively overexpressing IL-10 under control of the human CD68 promoter. J Immunol. 2002;168:3402-3411.